Glenmede Trust’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Glenmede Trust’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,558	Closed	-$18K	–	1357
2022 Q3	$18K	Buy	+11,558	New	+$26.2K	﹤0.01%	1225
2021 Q1	–	Sell	-29,257	Closed	-$199K	–	1276
2020 Q4	$199K	Buy	29,257 +122	+0.4%	+$980	﹤0.01%	1062
2020 Q3	$324K	Sell	29,135 -200	-0.7%	-$1.83K	﹤0.01%	900
2020 Q2	$184K	Buy	29,335 +200	+0.7%	+$766	﹤0.01%	1031
2020 Q1	$98K	Hold	29,135	–	–	﹤0.01%	1428
2019 Q4	$98K	Hold	29,135	–	–	﹤0.01%	1428
2019 Q3	$62K	Hold	29,135	–	–	﹤0.01%	1561
2019 Q2	$77K	Hold	29,135	–	–	﹤0.01%	1497
2019 Q1	$138K	Hold	29,135	–	–	﹤0.01%	1309
2018 Q4	$69K	Hold	29,135	–	–	﹤0.01%	1464
2018 Q3	$128K	Hold	29,135	–	–	﹤0.01%	1257
2018 Q2	$210K	Hold	29,135	–	–	﹤0.01%	1053
2018 Q1	$110K	Hold	29,135	–	–	﹤0.01%	1370
2017 Q4	$110K	Hold	29,135	–	–	﹤0.01%	1370
2017 Q3	$49K	Hold	29,135	–	–	﹤0.01%	1659
2017 Q2	$115K	Hold	29,135	–	–	﹤0.01%	1346
2017 Q1	$115K	Hold	29,135	–	–	﹤0.01%	1346
2016 Q4	$142K	Hold	29,135	–	–	﹤0.01%	1298
2016 Q3	$225K	Hold	29,135	–	–	﹤0.01%	1163
2016 Q2	$163K	Hold	29,135	–	–	﹤0.01%	1234
2016 Q1	$156K	Hold	29,135	–	–	﹤0.01%	1227
2015 Q4	$253K	Hold	29,135	–	–	﹤0.01%	1113
2015 Q3	$244K	Buy	+29,135	New	+$464K	﹤0.01%	1130

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Glenmede Trust's SRNE Position: Q4 2022 in Review

Glenmede Trust sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 11,558 shares — an estimated $18K sold.

Glenmede Trust first reported a position in SRNE in Q3 2015 and held it in 23 quarters. The position peaked at $324K in Q3 2020. 221 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

Glenmede Trust reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Glenmede Trust sold 11,558 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $18K.
Glenmede Trust first reported a position in Sorrento Therapeutics, Inc. in Q3 2015 and held it in 23 quarters.
Glenmede Trust's Sorrento Therapeutics, Inc. position peaked at $324K in Q3 2020.
221 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on Glenmede Trust's 13F filing for Q4 2022, filed 14 Feb 2023.